Integra LifeSciences (NASDAQ:IART) Stock Gets Price Target Reduction from Truist Financial

Integra LifeSciences (NASDAQ:IART) had its price objective trimmed by Truist Financial from $19.00 to $15.00 in a report released on Wednesday morning,Benzinga reports. The brokerage currently has a hold rating on the life sciences company’s stock.

A number of other brokerages have also issued reports on IART. Citigroup reaffirmed a “neutral” rating and set a $15.00 price target (down from $19.00) on shares of Integra LifeSciences in a research note on Monday, October 5th. Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. UBS Group initiated coverage on Integra LifeSciences in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price objective on the stock. Weiss Ratings lowered Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Finally, Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $16.71.

Integra LifeSciences Stock Down 2.4%

Integra LifeSciences stock opened at $13.21 on Wednesday. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -146.76, a PEG ratio of 0.72 and a beta of 1.21. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The company’s 50-day moving average price is $15.82 and its two-hundred day moving average price is $15.45. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, analysts expect that Integra LifeSciences will post 2.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio acquired a new stake in shares of Integra LifeSciences during the second quarter worth $82,000. Integrated Wealth Concepts LLC acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at $84,000. Sequoia Financial Advisors LLC boosted its position in shares of Integra LifeSciences by 27.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 3,059 shares during the period. Amundi boosted its position in shares of Integra LifeSciences by 80.8% in the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after purchasing an additional 8,681 shares during the period. Finally, Corient Private Wealth LP increased its stake in Integra LifeSciences by 66.9% in the 2nd quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock worth $409,000 after purchasing an additional 9,120 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.